View in EDS HTML Full Text PDF Full Text

Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.

Saved in:
Bibliographic Details
Title: Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
Authors: Imai, Hisao1,2 (AUTHOR) m06701014@gunma-u.ac.jp, Wasamoto, Satoshi3 (AUTHOR), Tsuda, Takeshi4 (AUTHOR), Nagai, Yoshiaki5 (AUTHOR), Kishikawa, Takayuki6 (AUTHOR), Masubuchi, Ken2 (AUTHOR), Osaki, Takashi7 (AUTHOR), Miura, Yosuke8 (AUTHOR), Umeda, Yukihiro9 (AUTHOR), Ono, Akihiro10 (AUTHOR), Minemura, Hiroyuki11 (AUTHOR), Yamada, Yutaka12 (AUTHOR), Nakagawa, Junichi13 (AUTHOR), Kozu, Yuki3 (AUTHOR), Taniguchi, Hirokazu4 (AUTHOR), Ohta, Hiromitsu5 (AUTHOR), Kasai, Takashi6 (AUTHOR), Kaira, Kyoichi1 (AUTHOR), Kagamu, Hiroshi1 (AUTHOR)
Source: Thoracic Cancer. Sep2023, Vol. 14 Issue 25, p2567-2578. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17597706
DOI:10.1111/1759-7714.15036